C4X Discovery Holdings PLC
LSE:C4XD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
C4X Discovery Holdings PLC
Revenue
C4X Discovery Holdings PLC
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
C4X Discovery Holdings PLC
LSE:C4XD
|
Revenue
£24.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Revenue
£223.9m
|
CAGR 3-Years
4%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Revenue
£32.2m
|
CAGR 3-Years
32%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
G
|
Genedrive PLC
LSE:GDR
|
Revenue
£1.2m
|
CAGR 3-Years
158%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-12%
|
|
|
Fusion Antibodies PLC
LSE:FAB
|
Revenue
£1.6m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
hVIVO PLC
LSE:HVO
|
Revenue
£46.8m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
18%
|
CAGR 10-Years
19%
|
|
C4X Discovery Holdings PLC
Glance View
C4X Discovery Holdings Plc engages in the development of new technologies to improve the drug discovery process for novel small molecule therapies. The firm operates by early commercial partnering or initiation of a its drug discovery program to develop a small molecule. The firm also works in collaboration with partners. The firm has a portfolio ranging from early stage-target to late-stage drug discovery program ready for out-licensing to partners. The Company’s portfolio of pre-clinical small molecule candidates includes Oral NRF2 activator, Oral MALT1 inhibitor, Oral α4β7 integrin inhibitor, Oral Orexin-1 Antagonist (C4X_3256/INDV-2000), Oral IL-17A Inhibitor. The company has developed activators of the NRF2 pathway for the treatment of a variety of inflammatory diseases including Inflammatory Bowel Disease (IBD), Sickle Cell Disease (SCD), Pulmonary Arterial Hypertension (PAH) and Chronic Obstructive Pulmonary Disorder (COPD).
See Also
What is C4X Discovery Holdings PLC's Revenue?
Revenue
24.7m
GBP
Based on the financial report for Jan 31, 2024, C4X Discovery Holdings PLC's Revenue amounts to 24.7m GBP.
What is C4X Discovery Holdings PLC's Revenue growth rate?
Revenue CAGR 5Y
28%
Over the last year, the Revenue growth was 473%.
